Experience

Excision BioTherapeutics

• United States
• Biotechnology
• 1 - 100 Employee

• Director Clinical Operations

  • Jun 2021 - Nov 2023



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Clinical Operations Consultant

  • Nov 2020 - Jun 2021

  Acquired MyoKardia in November 2020 Acquired MyoKardia in November 2020



MyoKardia

• United States
• Biotechnology Research
• 1 - 100 Employee

• Clinical Operations Consultant

  • Sep 2018 - Nov 2020

  US clinical operations lead for the pivotal Phase III and long-term extension studies in obstructive hypertrophic cardiomyopathy program. Camzyos (mavacamten) FDA approved, 2022. via Advanced Clinical US clinical operations lead for the pivotal Phase III and long-term extension studies in obstructive hypertrophic cardiomyopathy program. Camzyos (mavacamten) FDA approved, 2022. via Advanced Clinical



Genentech

• United States
• Biotechnology Research
• 700 & Above Employee

• Contract Global Studies Manager

  • Apr 2015 - Apr 2018

  Global manager for two late-stage natural history studies observing patients with age-related macular degeneration. Partnered with country affiliates in Argentina, Brazil, Colombia, Australia, Poland, France, Germany, and UK. via PRO Unlimited Global manager for two late-stage natural history studies observing patients with age-related macular degeneration. Partnered with country affiliates in Argentina, Brazil, Colombia, Australia, Poland, France, Germany, and UK. via PRO Unlimited



Gilead Sciences

• United States
• Biotechnology Research
• 700 & Above Employee

• Clinical Research Contractor

  • Dec 2012 - Dec 2014

  In-house operations support for two late phase global registry studies observing patients treated for hepatitis C. Sovaldi (sufosbuvir) FDA approved, 2013. via Aerotek Scientific In-house operations support for two late phase global registry studies observing patients treated for hepatitis C. Sovaldi (sufosbuvir) FDA approved, 2013. via Aerotek Scientific



InterMune

• Biotechnology
• 1 - 100 Employee

• Clinical Research Contractor

  • Feb 2012 - Jul 2012



FibroGen, Inc.

• United States
• Biotechnology Research
• 300 - 400 Employee

• Senior CRA

  • Jan 2011 - Aug 2011



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Clinical Trial Manager

  • Mar 2010 - Jan 2011

  Clinical trial manager in the influenza vaccine program, including seasonal, pre-pandemic (H5N1) and pandemic (H1N1) influenza vaccine studies.

• Clinical Research Associate

  • Oct 2005 - Feb 2010

  Contributions acknowledged in "A dose-ranging study of MF59-adjuvanted and non adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination," Human Vaccines and Immunotherapeutics, 2014.



PPD

• United States
• Research Services
• 700 & Above Employee

• Clinical Research Associate

  • Feb 2001 - Aug 2005

  Study monitor conducting on-site visits for Phase III studies in pediatric vaccines and prostate cancer. Based in Cambridge UK from 2004 to 2005. Study monitor conducting on-site visits for Phase III studies in pediatric vaccines and prostate cancer. Based in Cambridge UK from 2004 to 2005.